.png)
SummaryAut-idem, rebate contracts, the substitution-exclusion list and the reference-price transparency list are usually explained one at a time, by different sources. For a payer, a manufacturer or a market-access team the useful view is the opposite: how they interact to decide what is dispensed and at what net price. This guide connects them into one data story. It is written for professionals, not patients.
Aut-idem, Latin for “or the same”, is the rule that a pharmacy dispenses a therapeutically equivalent product rather than the exact brand prescribed, unless the prescriber rules substitution out. The framework agreement under section 129 SGB V governs when substitution is required. Substitution is not free choice; it follows a defined priority.
The order of dispensing is fixed, and it decides which product actually reaches the patient.
| Priority | Condition | Price anchor |
|---|---|---|
| 1. Rebate-contract product | the insurer has a rebate contract for the substance | rebate contract |
| 2. The specifically named PZN | substitution is excluded (aut-idem cross or exclusion list) | as prescribed |
| 3. One of the four lowest-priced products | no rebate contract and no exclusion | price anchor, section 12 framework agreement |
The practical consequence: a rebate contract usually wins, which is why rebate-contract coverage is a competitive signal, not just a dispensing rule.
Some active ingredients have such a narrow therapeutic index that switching brands carries a clinical risk, so they are excluded from substitution. The list is maintained through the aut-idem provisions of the G-BA.
| Active ingredient (examples) | Reason |
|---|---|
| Levothyroxine | narrow therapeutic index |
| Digitoxin / digoxin | narrow therapeutic index |
| Carbamazepine (sustained-release) | narrow therapeutic index |
| Valproic acid (sustained-release) | narrow therapeutic index |
The reference price (Festbetrag) caps what statutory health insurance reimburses for a defined group; anything above it is paid by the patient. The AVWG transparency list links products to these reference prices and reimbursement information, so a price comparison for a substance shows the originator, the generics and any reimport against the same reference-price line. Without it, a team reconstructs the picture from separate sources.
The list price is not the price a payer pays. Manufacturer rebates under section 130a SGB V and confidential rebate contracts between an insurer and a manufacturer reduce it. That is why the same product can have one list price and several effective net prices depending on the insurer. Modelling the net price means combining the list price, the statutory rebates and the rebate-contract status.
Rebate-contract data is insurer-specific: each fund publishes its own contracts. For a manufacturer or a market-access team the question is cross-insurer, is this substance under contract, with whom, and where is the whitespace, which no single insurer source answers. A consolidated view by PZN or active ingredient turns that scattered picture into one query. The generics side is covered in our guide to a market-access and reimbursement tool.
For manufacturers, rebate-contract coverage and reference-price position are competitive and revenue signals, not just dispensing mechanics. For market-access teams, the substitution logic and the transparency list decide where a product can defend its price. For payers, the interaction of aut-idem, rebate contracts and reference prices is the lever on spend. All three need the same data joined, which is the case for a consolidated platform. For the German pricing detail, see our pharma pricing and market access page.
Aut-idem, rebate contracts, the substitution-exclusion list and the reference-price transparency list are one system, not four topics. Seeing them together, the dispensing priority, the excluded substances, the reference-price line and the rebate status, is what turns a substitution question into a pricing decision. pharmazie.com is the consolidated pharmaceutical data platform by DACON Datenbank Consulting GmbH that bundles 25+ specialist databases into a single search, exclusively for healthcare professionals, and brings aut-idem, rebate-contract information and the AVWG transparency list into one view. The clearest way to see it is a short demo.
Further reading: Market-access and reimbursement tools · Pharma pricing and market access
